<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 11, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01937130</url>
  </required_header>
  <id_info>
    <org_study_id>IDN-6556-02</org_study_id>
    <nct_id>NCT01937130</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF</brief_title>
  <official_title>A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Conatus Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Conatus Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the pharmacokinetics, pharmacodynamics, safety and preliminary
      efficacy of IDN-6556 in subjects with cirrhosis of the liver who are hospitalized for more
      than 24 hours due to acute deterioration of liver function.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Data needs met
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>28 days</time_frame>
    <description>Primary endpoints for AUC_0-8, AUC_0 last, AUC_0-inf on Day 1 and Day 4 for the active treatment arms were analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>28 Days</time_frame>
    <description>Primary endpoints forCmax on Day 1 and Day 4 for the active treatment arms were analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax &amp; t1/2 Parameters</measure>
    <time_frame>28 Days</time_frame>
    <description>Primary endpoints for tmax &amp; t1/2 on Day 1 and Day 4 for the active treatment arms were analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of CK18/M30</measure>
    <time_frame>Baseline, Day 2, Day 4, Day 7, Day 14, Day 21, and Day 28</time_frame>
    <description>Caspase-cleaved cytokeratin serum levels (CK18/M30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of CK18/M65</measure>
    <time_frame>Baseline, Day 2, Day 4, Day 7, Day 14, Day 21, and Day 28</time_frame>
    <description>Caspase full-length cytokeratin serum levels CK18/M65</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Caspase 3/7 RLU</measure>
    <time_frame>Baseline, Day 2, Day 4, Day 7, Day 14, Day 21, and Day 28</time_frame>
    <description>Concentration of Caspase 3/7 Relative Light Units</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Acute on Chronic Hepatic Failure</condition>
  <condition>Acute Liver Failure</condition>
  <condition>Liver Cirrhosis</condition>
  <condition>Acute Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>IDN-6556 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosed twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDN-6556 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosed twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDN-6556 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosed twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosed twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDN-6556</intervention_name>
    <arm_group_label>IDN-6556 5 mg</arm_group_label>
    <arm_group_label>IDN-6556 25 mg</arm_group_label>
    <arm_group_label>IDN-6556 50 mg</arm_group_label>
    <other_name>emricasan</other_name>
    <other_name>PF-03491390</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects of minimum adult legal age (according to local laws for
             signing the informed consent document), able to provide written informed consent, and
             understand and comply with the requirements of the study

          -  Subjects with a clinical, radiological and/or histological diagnosis of cirrhosis

          -  Subjects having not required hospital admission within 4 weeks of screening for a
             complication of cirrhosis

          -  Subjects with an acute deterioration of liver function

          -  Subjects who meet one of the following criteria:

               1. Subjects with renal failure (defined as creatinine ≥ 2.0 to ≤ 3.4 mg/dL)

               2. Subjects with other single organ failure with i. Renal impairment (defined as an
                  increase in creatinine of &gt; 0.3 mg/dL from either an established prior Baseline
                  level or if applicable, upon admission to hospital if prior level is unavailable;
                  for inclusion, the creatinine level must be raised above normal levels), and/or
                  ii. Hepatic encephalopathy grade I or II

               3. Subjects with two organ failures

          -  If a subject received steroids for alcohol-induced acute liver failure, he/she must be
             unresponsive to steroid therapy. Responsiveness is based on investigator discretion.

          -  Willingness to utilize two reliable forms of contraception (for both males and females
             of childbearing potential) from screening to one month after the last dose of study
             drug

        Exclusion Criteria:

          -  Known infection with HIV

          -  Subjects with cirrhosis who develop decompensation at any time in the postoperative
             period following partial hepatectomy

          -  Subjects with evidence of uncontrolled infection defined as persistent bacterial
             culture positivity despite adequate antibiotic therapy

          -  Subjects with clinical evidence of disseminated intravascular coagulation

          -  Subjects with chronic and/or pre-existing kidney disease defined as eGFR (estimated
             glomerular filtration rate) of less than 30 mL/min for 3 months or longer

          -  Subjects who are hypotensive (defined as mean arterial pressure &lt;70 mmHg) or require
             the use of inotropic support

          -  Subjects with evidence of significant and/or uncontrolled bleeding

          -  Subjects requiring mechanical ventilation

          -  Subjects with active or history of malignancies other than hepatocellular carcinoma
             (HCC) within Milan criteria or curatively treated skin cancer (basal cell or squamous
             cell carcinomas), unless adequately treated or in complete remission for five or more
             years

          -  Subjects previously exposed to IDN-6556

          -  History or presence of clinically concerning cardiac arrhythmias, or prolongation of
             Screening (pre-treatment) QT or QTc interval of &gt; 480 milliseconds (msec)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Ryder, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nottingham University Hospital NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Pacific Medical Foundation</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerisity of Louisville Liver Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <state>Wales</state>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basildon and Thurrock University Hospital</name>
      <address>
        <city>Basildon</city>
        <zip>SS16 5NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London, Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospitals NHS Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle upon tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 28, 2016</lastchanged_date>
  <firstreceived_date>September 4, 2013</firstreceived_date>
  <firstreceived_results_date>February 26, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Failure</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Alcoholic Hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <!-- Results are available for this study                                                     -->
</clinical_study>
